Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound sirolimus injection plus fulvestrant versus placebo plus fulvestrant after CDK4/6 inhibitor treatment in HR-positive/HER2-negative advanced breast cancer
CTR20251319Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sirolimus, fulvestrant in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started May 2025; status: active.
02
Drugs
sirolimusfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20251319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251319.